Search
MSK researchers have discovered a new mechanism of resistance to KRAS inhibitors that suggests an opportunity to make the treatment more effective.
Physician-scientist Michael S. Glickman specializes in the treatment and study of infectious diseases.
MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.
Tumor genomics and clinicopathologic features better predict recurrent lung adenocarcinoma (LUAD) following primary resection compared with the TNM classification system, according to a recent study from MSK.
To help some patients to overcome leukemia, MSK doctors are calling upon patients’ microbiomes — the vast ecosystems of microorganisms that live within us, especially the gut. These microbes appear to help some patients recover from bone marrow and stem cell transplants.
Seven GSK PhD students were awarded nine competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science Foundation (NSF).
Researchers from Memorial Sloan Kettering Cancer Center to present the latest advances in blood cancer during The American Society of Hematology 2024 annual meeting.
About a third of patients with metastatic breast cancer don’t respond well to the standard anti-estrogen therapies; to find ways to better treat those patients, Memorial Sloan Kettering Cancer Center is studying three new selective estrogen receptor down-regulators (SERDs) in clinical trials.
MSK researchers continued to make strides against cancer in 2024. Learn about some of their top discoveries.
Memorial Sloan Kettering Cancer Center recently published two retrospective studies with practice-changing insights for improving the treatment and surveillance of patients with oropharyngeal cancer.